Pyrimidinylpiperazine anxiolytic drugs-ipsapirone, buspirone and gepirone-dose- dependently increased punished responding in an anticonflict (shock-induced suppression of drinking) paradigm in rats. Similar effect was also produced by their common metabolite 1- (2-pyrimidinyl)piperazine (1-PP). Anticonflict effects of ipsapirone, buspirone and gepirone, administered in maximal doses, were considerably stronger when tested 30 min than 120 min after their administration. Furthermore, anticonflict effects of these drugs, given in subthres hold or medium effective doses, were significantly potentiated by the non-selective drug metabolism inhibitor proadifen. Comparison of these results with literature pharmacokinetic data indicate that the pharmacological effect of ipsapirone, buspirone and gepirone parallels better cerebral concentrations of the parent drugs than 1-PP. Therefore anticonflict activity of the investigated drugs does not seem to be mediated by their common metabolite 1-PP.
Get full access to this article
View all access options for this article.
References
1.
Anders M.W.1971Enhancement of drug metabolismAnnual Review of Pharmacology11: 37-52
2.
Bianchi G., Caccia S., Vedova F.D., Garattini S.1988The α2adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP)European Journal of Pharmacology151: 365-371
3.
Bianchi G., Garattini S.1988Blockade of α2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspironeEuropean Journal of Pharmacology147: 343-350
4.
Caccia S., Conti I., Vigano G., Garattini S.19861-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and ratPharmacology33: 46-51
5.
Caccia S., Muglia M., Mancinelli A., Garattini S.1983Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the ratXenobiotics13: 147-153
6.
Cott J.M., Kurtz N.M., Robmson D.S., Lancaster S.P., Copp J.E.1988A 5-HT1A ligand with both antidepressant and anxiolytic propertiesPsychopharmacology Bulletin24: 164-167
7.
Danek L., Nocoń H., Tarnawska A., Melzacka M.1987The TLC-HPLC study of ipsapirone (TVX Q 7821) metabolism in rats. In Proceedings of the 4th Annual American-Eastern European Symposium on Advances in Liquid Chromatography (eds Kalasz H, Ettre L S). Budapest, Hungary, pp 153-158
8.
Eison A.S., Eison M.S., Stanley M., Riblet L.A.1986Serotonergic mechanism in the behavioral effects of buspirone and gepironePharmacology Biochemistry and Behaviour24: 701-707
9.
Gammans R.E., Mayol R.F., Labudde J.A.1986Metabolism and disposition of buspironeAmerican Journal Medicine80: 41-51
10.
Giral P., Soubrie P., Puech A.J.1987Pharmacological evidence for the involvement of 1-(2-pyrimidinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systemsEuropean Journal of Pharmacology134: 113-116
11.
Goldberg H., Finnerty R.1979The comparative efficacy of buspirone and diazepam in the treatment of anxietyAmerican Journal of Psychiatry136: 1184-1187
12.
Gower A.J., Tricklebank M.D.1988α2-Adrenoceptor antagomst activity may account for the effects of buspirone in an anticonflict test in the ratEuropean Journal of Pharmacology155: 129-137
13.
Kuemmel B., Beneke M., Krol G., Schoellnhammer G., Spechtmeyer H.1988Ipsapirone in the treatment of generalized anxiety disorders. Results of a phase II US-multicenter trialPsychopharmacology Suppl96: 353
14.
McMillen B.A., Scott S.M., Williams H.L., Sanghera M.K.1987Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behaviour and brain monoaminergic neurotransmissionNaunyn-Schmiedeberg's Archives of Pharmacology335: 454-464
15.
Nocoń H., Daniel W., Danek L., Melzacka M.1989Cerebral pharmacokinetics of ipsapirone (TVX Q 7821) in rats after different routes of administrationJournal of Pharmacy Pharmacology, in press
16.
Peroutka S.J.1985Selective interaction of novel anxiolytics with 5-hydroxytryptamine 1A receptorsBiological Psychiatry20: 971-979
17.
Riblet L., Taylor D., Eison M., Stanton H.1982Pharmacology and neurochemistry of buspironeJournal Clinical Psychiatry43: 11-18
18.
Rimele T.J., Henry D.E., Lee D K H, Geiger G., Heaslip R.J., Grimes D.1987Tissue-dependent alpha-adrenoceptor activity of buspirone and related compoundsJournal of Pharmacology and Experimental Therapy241: 771-778
19.
Saari W.S., Halczenko W., King S.W., Huff J.R., Guare J.P., Hunt C.A., Randall W.C., Anderson P.S., Lotti V.J., Taylor D.A., Clineschmidt B.V.1983Pyridinylpiperazines, a new class of selective α 2-adrenoceptor antagonistsJournal Medical Chemistry26: 1696-1701
20.
Tatarczyńska E., Pawlowski L., Chojnacka-Wójcik E., Maj J.1989The central action of 1-(2-pyrimidinyl)-piperazine, an ipsapirone metabolitePolish Journal of Pharmacology and Pharmacology41: 51-61
21.
Traber J., Davies M.A., Dompert W.U., Glaser T., Schuurman T., Seidel P.R.1984Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821Brain Research Bulletin12: 741-744
22.
Traber J., Glaser T.19875-HT1A receptor-related anxiolyticsTrends in Pharmacological Science8: 432-437
23.
Traber J., Schuurman T., Benz U.1988A comparison of the 5-HT1A receptor-related anxiolytics buspirone, gepirone, ipsapirone, SM-3997, their common metabolite 1-PP and diazepam in animal models of anxietyPsychopharmacology suppl96: 352
24.
Vogel J.R., Beer B., Clody D.E.1971A simple and reliable conflict procedure for testing antianxiety agentsPsychopharmacologia21: 1-7
25.
Weissman B.A., Barrett J.E., Brady L.S., Witkin J.M., Mendelson W.B., Paul S.M., Skolnick P.1984Behavioral and neurochemical studies on the anticonflict actions of buspironeDrug Development and Research4: 83-93
26.
Young R., Urbanic A., Emrey T.A., Hall P.C., Metcalf G.1987Behavioural effects of several new anxiolytics and putative anxiolyticsEuropean Journal of Pharmacology143: 361-371
